Increlex for Severe primary IGF-1 deficiency
Quick answer: Increlex is used for Severe primary IGF-1 deficiency as part of a recombinant human insulin-like growth factor-1 (rhigf-1) treatment regimen. Recombinant IGF-1 (mecasermin) replaces deficient endogenous IGF-1 to promote linear growth The specific dosing for Severe primary IGF-1 deficiency is determined by your prescriber based on individual factors.
Why is Increlex used for Severe primary IGF-1 deficiency?
Increlex belongs to the Recombinant human insulin-like growth factor-1 (rhIGF-1) class. Recombinant IGF-1 (mecasermin) replaces deficient endogenous IGF-1 to promote linear growth This action makes it useful for treating or managing Severe primary IGF-1 deficiency in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Increlex is the right choice for a specific patient depends on the type and severity of Severe primary IGF-1 deficiency, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Severe primary IGF-1 deficiency
Common adult dosing range: 0.04-0.12 mg/kg subcutaneously twice daily. The actual dose for Severe primary IGF-1 deficiency depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Increlex medicine page.
What to expect
Increlex treatment for Severe primary IGF-1 deficiency typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Severe primary IGF-1 deficiency
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Increlex is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all Recombinant human insulin-like growth factor-1 (rhIGF-1) for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Increlex
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Increlex full prescribing information · All Recombinant human insulin-like growth factor-1 (rhIGF-1) alternatives
Frequently asked questions
How effective is Increlex for Severe primary IGF-1 deficiency?
Effectiveness varies by individual response, dose, and severity. Increlex is one of several treatment options for Severe primary IGF-1 deficiency, supported by clinical evidence within the recombinant human insulin-like growth factor-1 (rhigf-1) class. Discuss expected response with your prescriber.
How long do I need to take Increlex for Severe primary IGF-1 deficiency?
Treatment duration depends on the nature of Severe primary IGF-1 deficiency — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Increlex when used for Severe primary IGF-1 deficiency?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Increlex for Severe primary IGF-1 deficiency?
Yes. Multiple medicines and non-drug options exist for Severe primary IGF-1 deficiency. Alternatives within the recombinant human insulin-like growth factor-1 (rhigf-1) class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.